These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 29784014)

  • 1. Unintentional sulfonylurea toxicity due to a drug-drug interaction: a case report.
    Gunaratne K; Austin E; Wu PE
    BMC Res Notes; 2018 May; 11(1):331. PubMed ID: 29784014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas.
    Ragia G; Petridis I; Tavridou A; Christakidis D; Manolopoulos VG
    Pharmacogenomics; 2009 Nov; 10(11):1781-7. PubMed ID: 19891554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Octreotide for the treatment of sulfonylurea poisoning.
    Glatstein M; Scolnik D; Bentur Y
    Clin Toxicol (Phila); 2012 Nov; 50(9):795-804. PubMed ID: 23046209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Refractory Hypoglycemia Due to Sulfonylurea Contamination of Illicit Opioid Medications.
    Savarino JR; Mokszycki R; Tubbs R; Wightman RS
    R I Med J (2013); 2024 May; 107(5):11-13. PubMed ID: 38687261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Successful treatment of severe sulfonylurea-induced hypoglycemia by the subcutaneous administration of octreotide in an elderly patient with diabetes: A case report].
    Nakaya M; Oka R; Miyamoto S
    Nihon Ronen Igakkai Zasshi; 2019; 56(3):336-342. PubMed ID: 31366755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Octreotide: an antidote for sulfonylurea-induced hypoglycemia.
    McLaughlin SA; Crandall CS; McKinney PE
    Ann Emerg Med; 2000 Aug; 36(2):133-138. PubMed ID: 10918104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoglycemia in Frail Elderly Patients With Type 2 Diabetes Mellitus Treated With Sulfonylurea.
    van Dijk P; Bouma A; Landman GW; Groenier KH; Bilo H; Kleefstra N; van Hateren KJ
    J Diabetes Sci Technol; 2017 Mar; 11(2):438-439. PubMed ID: 27625346
    [No Abstract]   [Full Text] [Related]  

  • 8. Toxicology of oral antidiabetic medications.
    Spiller HA; Sawyer TS
    Am J Health Syst Pharm; 2006 May; 63(10):929-38. PubMed ID: 16675650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Octreotide therapy for recurrent refractory hypoglycemia due to sulfonylurea in diabetes-related kidney failure.
    Gonzalez RR; Zweig S; Rao J; Block R; Greene LW
    Endocr Pract; 2007; 13(4):417-23. PubMed ID: 17669721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of octreotide and standard therapy versus standard therapy alone for the treatment of sulfonylurea-induced hypoglycemia.
    Fasano CJ; O'Malley G; Dominici P; Aguilera E; Latta DR
    Ann Emerg Med; 2008 Apr; 51(4):400-6. PubMed ID: 17764782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction between voriconazole and glimepiride.
    Shobha JC; Muppidi MR
    J Postgrad Med; 2010; 56(1):44-5. PubMed ID: 20393255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study.
    Abdelmoneim AS; Eurich DT; Gamble JM; Johnson JA; Seubert JM; Qiu W; Simpson SH
    Diabetes Obes Metab; 2014 Jan; 16(1):22-9. PubMed ID: 23802997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment.
    Harrigan RA; Nathan MS; Beattie P
    Ann Emerg Med; 2001 Jul; 38(1):68-78. PubMed ID: 11423816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is gliclazide a sulfonylurea with difference? A review in 2016.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2016 Jun; 9(6):839-51. PubMed ID: 26924475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Octreotide for sulfonylurea-induced hypoglycemia following overdose.
    Carr R; Zed PJ
    Ann Pharmacother; 2002 Nov; 36(11):1727-32. PubMed ID: 12398568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of subcutaneous octreotide in patients with sulfonylurea-induced hypoglycemia and congestive heart failure.
    Vallurupalli S
    Ann Pharmacother; 2010 Feb; 44(2):387-90. PubMed ID: 20118140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HYPOGLYCEMIA INDUCED BY ANTIDIABETIC SULFONYLUREAS.
    Confederat L; Constantin S; Lupaşcu F; Pânzariu A; Hăncianu M; Profire L
    Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):579-84. PubMed ID: 26204670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABCC8 polymorphism (Ser1369Ala): influence on severe hypoglycemia due to sulfonylureas.
    Sato R; Watanabe H; Genma R; Takeuchi M; Maekawa M; Nakamura H
    Pharmacogenomics; 2010 Dec; 11(12):1743-50. PubMed ID: 21142918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of sulfonylurea agents in older diabetic patients.
    Peters AL; Davidson MB
    Clin Geriatr Med; 1990 Nov; 6(4):903-21. PubMed ID: 2224754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible interaction between gliclazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.
    Abad S; Moachon L; Blanche P; Bavoux F; Sicard D; Salmon-Céron D
    Br J Clin Pharmacol; 2001 Oct; 52(4):456-7. PubMed ID: 11678792
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.